Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine
暂无分享,去创建一个
Miklós Palkovits | Katarína Šebeková | M. Palkovits | A. Heidland | G. Fazeli | U. Bahner | August Heidland | Udo Bahner | Anton Kebis | Gholamreza Fazeli | Kristina Simon Klenovics | A. Kebis | K. S. Klenovics | K. Šebeková | Gholamreza Fazeli
[1] M. Selley. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease , 2003, Neurobiology of Aging.
[2] D. Tanné,et al. Kidney function is associated with the rate of cognitive decline in the elderly , 2009, Neurology.
[3] E. Timofeeva,et al. Activation of the central nervous system in obese Zucker rats during food deprivation , 2001, The Journal of comparative neurology.
[4] H. Haas,et al. The role of histamine and the tuberomamillary nucleus in the nervous system , 2003, Nature Reviews Neuroscience.
[5] M. Bossola,et al. Anorexia in hemodialysis patients: an update. , 2006, Kidney international.
[6] V. Campese,et al. Losartan Reduces Central and Peripheral Sympathetic Nerve Activity in a Rat Model of Neurogenic Hypertension , 2002, Hypertension.
[7] R. Selgas,et al. Uremic Anorexia: A Consequence of Persistently High Brain Serotonin Levels? The Tryptophan/Serotonin Disorder Hypothesis , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[8] D. Holland,et al. Quality of sleep in patients with chronic kidney disease. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] J. Fischer,et al. Blood-brain barrier derangement in uremic encephalopathy. , 1982, Surgery.
[10] M. Goicochea,et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. , 2008, Kidney international. Supplement.
[11] P. Kotanko. Cause and Consequences of Sympathetic Hyperactivity in Chronic Kidney Disease , 2005, Blood Purification.
[12] A. Blomqvist,et al. Forebrain patterns of c‐Fos and FosB induction during cancer‐associated anorexia–cachexia in rat , 2005, The European journal of neuroscience.
[13] Scott D. Cohen,et al. Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[14] P. Jungers,et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. , 1998, Journal of immunology.
[15] J. Gutkowska,et al. Atrial natriuretic peptide is involved in renal actions of moxonidine. , 2000, Hypertension.
[16] T. Çaycı,et al. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] E. Ritz,et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. , 2000, Journal of the American Society of Nephrology : JASN.
[18] D. Knopman,et al. Cognitive impairment in hemodialysis patients is common , 2006, Neurology.
[19] M. Palkovits,et al. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain. , 2001, Pharmacological research.
[20] P. Wolf,et al. Association of Plasma ADMA Levels With MRI Markers of Vascular Brain Injury: Framingham Offspring Study , 2009, Stroke.
[21] G. Mancia,et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[22] Frank Donnerstag,et al. ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans , 2006, Stroke.
[23] T. Herdegen,et al. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins , 1998, Brain Research Reviews.
[24] P. Kimmel,et al. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. , 2006, Kidney international.
[25] R. Converse,et al. Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.
[26] R. Bigazzi,et al. Altered norepinephrine turnover in the brain of rats with chronic renal failure. , 1994, Journal of the American Society of Nephrology : JASN.
[27] P. Boor,et al. Neuronal activation in the CNS during different forms of acute renal failure in rats , 2009, Neuroscience.
[28] A. Heidland,et al. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.
[29] P. Riederer,et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress , 1998, Journal of Neural Transmission.
[30] K. Kelly. Distant effects of experimental renal ischemia/reperfusion injury. , 2003, Journal of the American Society of Nephrology : JASN.
[31] F. Kronenberg,et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.
[32] D. Reaich. Odour perception in chronic renal disease , 1997, The Lancet.
[33] M. Palkovits,et al. Atrial Natriuretic Peptide in Brain Preoptic Areas: Implications for Fluid and Salt Homeostasis , 1988, Journal of cardiovascular pharmacology.
[34] Mark McEvoy,et al. Asymmetric dimethylarginine: a possible link between vascular disease and dementia. , 2013, Current Alzheimer research.
[35] F. Dekker,et al. The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] M. Zeier,et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] C. Abbadie,et al. c-fos Expression in rat lumbar spinal cord during the development of adjuvant-induced arthritis , 1992, Neuroscience.
[38] M. Samuels,et al. Uremic encephalopathy and other brain disorders associated with renal failure. , 2011, Seminars in neurology.
[39] E. Senba,et al. Stress-induced hyperalgesia: animal models and putative mechanisms. , 2006, Frontiers in bioscience : a journal and virtual library.
[40] P. Blankestijn,et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. , 2004, Kidney international.
[41] E. Sabban,et al. Single and repeated immobilization stress differentially trigger induction and phosphorylation of several transcription factors and mitogen‐activated protein kinases in the rat locus coeruleus , 2005, Journal of neurochemistry.
[42] J. Fischer,et al. Blood-brain barrier derangement in sepsis: cause of septic encephalopathy? , 1981, American journal of surgery.
[43] D. Averill,et al. Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II andL-glutamate in rostral ventrolateral medulla , 1994, Brain Research.
[44] B. Prichard,et al. Moxonidine: a new antiadrenergic antihypertensive agent. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[45] S. Yusuf,et al. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. , 2011, Archives of internal medicine.
[46] K. Jellinger,et al. Brain monoamines in metabolic (endotoxic) coma a preliminary biochemical study in human postmortem material , 2005, Journal of Neural Transmission.
[47] S. Waldstein,et al. Renal Function and Cardiovascular Response to Mental Stress , 2007, American Journal of Nephrology.
[48] M. Palkovits,et al. Effect of ACE inhibitors on atrial natriuretic factor in the brains of rats with reduced renal mass. , 1993, Kidney international.
[49] E. Ritz,et al. Sympathetic overactivity and arterial hypertension in renal failure. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[50] M. Neil,et al. Clonidine: clinical pharmacology and therapeutic use in pain management. , 2011, Current clinical pharmacology.
[51] B. Landis,et al. Olfactory function improves following hemodialysis. , 2011, Kidney international.
[52] D. G. Laing,et al. Smell and taste function in children with chronic kidney disease , 2010, Pediatric Nephrology.
[53] H. Przuntek,et al. Increased histidine and histamine content in the brain of chronic uremic rats. Cause of enhanced cerebral cyclic adenosine monophosphate in uremia? , 1978, The American journal of clinical nutrition.
[54] P. D. De Deyn,et al. Marconi revisited: from kidney to brain--two organ systems communicating at long distance. , 2008, Journal of the American Society of Nephrology : JASN.
[55] E. Miller,et al. An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.
[56] J. Williamson,et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. , 2009, Archives of internal medicine.
[57] T. Hostetter,et al. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). , 2007, Journal of the American Society of Nephrology : JASN.
[58] B. Spiegel,et al. Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[59] I. Liu,et al. Sleep apnea in early and advanced chronic kidney disease: Kaiser Permanente Southern California cohort. , 2009, Chest.
[60] H. Critchley,et al. Brain systems for baroreflex suppression during stress in humans , 2012, Human brain mapping.
[61] S. Kuroda,et al. Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species , 2006, Brain Research.
[62] V. Campese,et al. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. , 1997, Kidney international.
[63] S. Tufik,et al. Genomic damage in the progression of chronic kidney disease in rats , 2011, Brain, Behavior, and Immunity.
[64] P. Blankestijn,et al. J Am Soc Nephrol 15: 524–537, 2004 Sympathetic Hyperactivity in Chronic Renal Failure: A Wakeup , 2022 .
[65] V. Wadley,et al. Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[66] A. Bomback,et al. Olfactory function in dialysis patients: a potential key to understanding the uremic state. , 2011, Kidney international.
[67] R. Casper,et al. Depression and eating disorders , 1998, Depression and anxiety.
[68] V. Campese,et al. Losartan reduces sympathetic nerve outflow from the brain of rats with chronic renal failure , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[69] A. Morrison. Experimentally induced chronic renal insufficiency in the rat. , 1962, Laboratory investigation; a journal of technical methods and pathology.
[70] J. Stamp,et al. Multiple immediate-early gene expression during physiological and endocrine adaptation to repeated stress , 1999, Neuroscience.
[71] P. Riederer,et al. Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[72] A. Abdelhafiz,et al. Microalbuminuria: Marker or Maker of Cardiovascular Disease , 2011, Nephron Experimental Nephrology.
[73] S. Seliger,et al. Chronic kidney disease, creatinine and cognitive functioning. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[74] Eduardo E. Benarroch,et al. The locus ceruleus norepinephrine system , 2009, Neurology.
[75] D. Morgan,et al. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[76] Giuseppe Mancia,et al. Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure , 2011, Hypertension.
[77] P. Deyn,et al. Neurological complications in renal failure: a review , 2004, Clinical Neurology and Neurosurgery.
[78] V. Campese,et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. , 2004, American journal of physiology. Heart and circulatory physiology.
[79] Paul J Thornalley,et al. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. , 2007, Kidney international.
[80] F. Grodstein,et al. Kidney dysfunction and cognitive decline in women. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[81] T. Singer,et al. The neural basis of empathy. , 2012, Annual review of neuroscience.
[82] K. Parker. Sleep disturbances in dialysis patients. , 2003, Sleep medicine reviews.
[83] S. Davison. Chronic pain in end-stage renal disease. , 2005, Advances in chronic kidney disease.
[84] L. Price,et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[85] T. Curran,et al. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. , 1991, Annual review of neuroscience.
[86] D. Knopman. Invited commentary: Albuminuria and microvascular disease of the brain--a shared pathophysiology. , 2010, American journal of epidemiology.
[87] A. Grandi,et al. Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade , 2002, Journal of hypertension.
[88] G. Fink,et al. Differential activation of memory-relevant brain regions during a dialysis cycle. , 2010, Kidney international.
[89] J. Slaets,et al. Association of cognitive function with albuminuria and eGFR in the general population. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[90] P. Ernsberger,et al. Pharmacology of moxonidine, an I1-imidazoline receptor agonist. , 1996, Journal of cardiovascular pharmacology.
[91] Takeo Kato,et al. Cerebral small vessel disease and chronic kidney disease (CKD): Results of a cross-sectional study in community-based Japanese elderly , 2008, Journal of the Neurological Sciences.
[92] R. Vanholder,et al. What is new in uremic toxicity? , 2008, Pediatric Nephrology.
[93] I. Reid. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.
[94] Morrison Ab. Experimentally induced chronic renal insufficiency in the rat. , 1962 .
[95] M. Cirillo,et al. A longitudinal study of sleep disorders in early-stage chronic kidney disease. , 2010, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[96] M. Koss,et al. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[97] M. Swendseid,et al. Brain serotonin turnover in chronically uremic rats. , 1977, The American journal of physiology.
[98] P. Ernsberger,et al. Pharmacology of Moxonidine, an I1‐Imidazoline Receptor Agonist , 2000, Journal of cardiovascular pharmacology.